| [1] |
Li W, Zhang C, Chen C, et al. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL[J]. Cell Mol Immunol,2007,4(6): 455-60.
|
| [2] |
Bamias G, Siakavellas SI, Stamatelopoulos KS, et al. Circulating levels of TNF-like cytokine 1A (TL1A) and its decoy receptor 3 (DcR3) in rheumatoid arthritis[J].Clin Immunol, 2008, 12 9(2):249-55.
|
| [3] |
Gill RM, Hunt JS. Soluble receptor (DcR3) and cellular inhibitor of apoptosis-2 (cIAP-2) protect human cytotrophoblast cells against LIGHT-mediated apoptosis[J]. Am J Pathol,2004, 165(1): 30 9-17.
|
| [4] |
Koichi O, Seiji H, Midori S, et al. Amplifi cation and expression of a decoy receptor for Fas ligand (DcR3) in virus (EBV or HTLV-I) associated lymphomas[J]. Cancer Lett,2000, 160(1): 89-97.
|
| [5] |
Chen L, Tian X, Li W, et al. Expressions of Fas/DcR3 and RGDFasL mediated apoptosis in pituitary adenomas[J]. Neurol India,2009, 57(1): 28-30 .
|
| [6] |
Mueller AM, Pedre X, Killian S, et al. The Decoy Receptor 3 (DcR3, TNFRSF6B) suppresses Th17 immune responses and is abundant in human cerebrospinal fl uid[J]. J Neuroimmunol,2009, 20 9(1-2): 57-64.
|
| [7] |
Macher-Goeppinger S, Aulmann S, Wagener N, et al. Decoy receptor 3 is a prognostic factor in renal cell cancer[J]. Neoplasia, 20 08,10(10):1049-56.
|
| [8] |
Pitti RM, Marsters SA, Lawrence DA, et al. Genomic amplifi cation of a decoy receptor for Fas ligand in lung and colon cancer[J]. Nature,1998, 396(6712):699-703.
|
| [9] |
Tsuji S, Hosotani R, Yonehara S, et al. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma[J]. Int J Cancer,2003, 10 6(1):17-25.
|
| [10] |
Morishige T, Yoshioka Y, Inakura H, et al. Creation of a LIGHT mutant with the capacity to evade the decoy receptor for cancer therapy[J]. Biomaterials,2010, 31(12):3357-63.
|
| [11] |
Yu KY, Kwon B, Ni J, et al. A newly identifi ed member of tumor necrosis factor receptor superfamily (TR6) suppresses LIGHTmediated apoptosis[J]. J Biol Chem,1999, 274(20):13733-6.
|
| [12] |
You RI, Chang YC, Chen PM, et al. Apoptosis of dendritic cell induced by decoy receptor 3(DcR3) [J]. Blood, 2008, 11 1(3):1480-8.
|
| [13] |
Yang CR, Hsieh SL, Teng CM, et al. Soluble decoy receptor 3 induces angiogenesis by neutralization of TL1A, a cytokine belonging to tumor necrosis factor superfamily and exhibiting angiostatic action[J]. Cancer Res,2004,64(3):1122-9.
|
| [14] |
Wu Y, Guo E, Yu J, et al. High DcR3 expression predicts stage pN2-3 in gastric cancer[J]. Am J Clin Oncol,2008,31(1):79-83.
|
| [15] |
Liang QL, Wang BR, Li GH. DcR3 and survivin are highly expressed in colorectal carcinoma and closely correlated to its clinicopathologic parameters[J]. J Zhejiang Univ Sci B,2009,10(9):675-82.
|
| [16] |
Li H, Zhang L, Lou H, et al. Overexpression of decoy receptor 3 in precancerous lesions and adenocarcinoma of the esophagus[J]. Am J Clin Pathol,2005,124(2):282-7.
|
| [17] |
Chen C,Zhang C,Zhuang G, et al. Decoy receptor 3 overexpression and immunologic tolerance in hepatocellular carcinoma (HCC) development[J]. Cancer Invest,??2008, 26(10):965-74.
|
| [18] |
Arakawa Y, Tachibana O, Hasegawa M, et al. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma[J]. Acta Neuropathol,2005,109(3):294-8.
|
| [19] |
Connor JP, Felder M. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance[J]. Gynecol Oncol, 20 08,111(2):330-5.
|
| [20] |
Hsu TL, Chang YC, Chen SJ, et al. Modulation of dendritic cell differentiation and maturation by decoy receptor 3[J]. J Immunol, 20 02,168(10):4846-53.
|
| [21] |
Hsu TL, Wu YY, Chang YC, et al. Attenuation of Th1 response in decoy receptor 3 transgenic mice[J]. J Immunol,2005,175(8):5135 -45.
|
| [22] |
Wu Y, Han B, Sheng H, et al. Clinical signifi cance of detecting elevated serum DcR3/TR6/M68 in malignant tumor patients[J]. Int J Cancer,2003,105(5):724-32.
|
下载:
